Developer docs
API playgroundTry for free, no card

Search company profiles

NEUVOGEN

Full company profile

uuid0008u6k

Namestring
NEUVOGEN
Legal namestring
NEUVOGEN, Inc.
Websiteurl
neuvogen.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

NEUVOGEN is a San Diego-based, privately held, clinical-stage biotechnology company developing off-the-shelf, whole-cell therapeutic cancer vaccines for solid tumors. The company applies a systems biology and data-driven engineering approach to build each vaccine from six genetically modified allogeneic tumor cell lines, enhanced with a proprietary activation technology designed to overcome peripheral tolerance and broaden tumor antigen presentation. Its lead candidate, NGEN-143, targets non-small cell lung cancer (NSCLC) and is supported by preclinical in vitro and in vivo data, including AACR 2025 data showing polyfunctional CD8+ T cell activation and improved survival when combined with anti-PD1 in mouse tumor models. The company has expanded a pipeline of 10 candidates (NGEN-143, -241, -121, -221, -181, -281, -261, -122, -242, -123) spanning NSCLC, prostate, colorectal, breast, head & neck, glioblastoma, bladder, gastric, ovarian, and pancreatic cancers.

The company is pre-revenue and not yet in clinical trials. Its business model contemplates future revenue from product sales following regulatory approval, supplemented by potential licensing, co-development, or acquisition transactions with larger pharmaceutical partners. Commercial distribution is expected to flow through hospital and specialty pharmacies and oncology centers, with the company signaling openness to partnership-based global commercialization. Scientific credibility has been reinforced by SAB additions including 2018 Nobel laureate James P. Allison and Padmanee Sharma of MD Anderson, and board leadership by former Amgen CEO Gordon Binder. A 2022 licensing agreement with ImaginAb provides CD8 Immuno-PET imaging for clinical trial pharmacodynamic readouts. No commercial customers, funding rounds, or revenue figures are disclosed in the available source data.

Short descriptiontext

NEUVOGEN is a San Diego-based, pre-revenue clinical-stage biotechnology company developing off-the-shelf, whole-cell therapeutic cancer vaccines built on a proprietary activation technology, with a pipeline of 10 candidates led by NGEN-143 for non-small cell lung cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer vaccines, whole cell immunotherapy, solid tumor therapeutics, immunoncology vaccines, allogeneic cell therapy
Industry3 codes
PRIMARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Therapeutic Cancer Vaccines
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Cancer Vaccines
TypeOne Time License
Description

NEUVOGEN is a pre-revenue clinical-stage biotechnology company developing therapeutic whole cell cancer vaccines. The company has not yet commercialized any products. Revenue generation is expected through product sales following regulatory approval, with potential for licensing agreements, co-development partnerships, or outright acquisition by larger pharmaceutical companies.

neuvogen.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1NGEN-143
Description

Lead product candidate - off-the-shelf therapeutic vaccine for non-small cell lung cancer (NSCLC), comprising six genetically modified allogeneic tumor cell lines enhanced with proprietary activation technology

neuvogen.com
+9 more records
Core offering1 text field

NEUVOGEN develops therapeutic whole cell cancer vaccines for solid tumor indications using a proprietary platform that combines six genetically modified allogeneic tumor cell lines per vaccine product. Each cell line is enhanced with proprietary activation technology to broaden tumor antigen presentation and drive broad T cell responses. Vaccines are manufactured as off-the-shelf, intradermally administered products, with the lead candidate NGEN-143 targeting non-small cell lung cancer and nine additional candidates covering prostate, colorectal, breast, head and neck, glioblastoma, bladder, gastric, ovarian, and pancreatic cancers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • NGEN-143 activates polyfunctional, cytotoxic T cells that efficiently kill human tumor cells in a caspase-3 dependent manner
+2 more records
Product overview1 text field

NEUVOGEN is a biotechnology company developing a platform of therapeutic whole cell cancer vaccines for solid tumors. The company's portfolio consists of ten product candidates (NGEN-143, NGEN-241, NGEN-121, NGEN-221, NGEN-181, NGEN-281, NGEN-261, NGEN-122, NGEN-242, and NGEN-123) targeting non-small cell lung cancer, prostate cancer, colorectal cancer, breast cancer, head and neck cancer, glioblastoma, bladder cancer, gastric cancer, ovarian cancer, and pancreatic cancer respectively. NGEN-143 for NSCLC is the lead program. Each vaccine is built on NEUVOGEN's proprietary whole tumor cell vaccine platform, which combines advanced bioinformatics for cell line selection, proprietary genetic engineering for enhanced tumor antigen expression, and a scalable manufacturing process. All products are designed as off-the-shelf, intradermally administered vaccines.

Product and service10 records
1NGEN-143
CategoryTherapeutic Cancer Vaccine
Description

NGEN-143 is NEUVOGEN's lead product candidate: an off-the-shelf therapeutic vaccine for non-small cell lung cancer (NSCLC) comprising six genetically modified allogeneic tumor cell lines, each enhanced with proprietary activation technology to broaden tumor antigen presentation and improve immune engagement. It is intended for oncology use and is administered intradermally in any clinical setting without patient-specific customization.

2NGEN-241
CategoryTherapeutic Cancer Vaccine
Description

NGEN-241 is a therapeutic cancer vaccine product candidate for prostate cancer, built on NEUVOGEN's proprietary activation technology platform.

3NGEN-121
CategoryTherapeutic Cancer Vaccine
Description

NGEN-121 is a therapeutic cancer vaccine product candidate for colorectal cancer, built on NEUVOGEN's proprietary activation technology platform.

4NGEN-221
CategoryTherapeutic Cancer Vaccine
Description

NGEN-221 is a therapeutic cancer vaccine product candidate for breast cancer, built on NEUVOGEN's proprietary activation technology platform.

5NGEN-181
CategoryTherapeutic Cancer Vaccine
Description

NGEN-181 is a therapeutic cancer vaccine product candidate for head and neck cancer, built on NEUVOGEN's proprietary activation technology platform.

6NGEN-281
CategoryTherapeutic Cancer Vaccine
Description

NGEN-281 is a therapeutic cancer vaccine product candidate for glioblastoma (GBM), built on NEUVOGEN's proprietary activation technology platform.

7NGEN-261
CategoryTherapeutic Cancer Vaccine
Description

NGEN-261 is a therapeutic cancer vaccine product candidate for bladder cancer, built on NEUVOGEN's proprietary activation technology platform.

8NGEN-122
CategoryTherapeutic Cancer Vaccine
Description

NGEN-122 is a therapeutic cancer vaccine product candidate for gastric cancer, built on NEUVOGEN's proprietary activation technology platform.

9NGEN-242
CategoryTherapeutic Cancer Vaccine
Description

NGEN-242 is a therapeutic cancer vaccine product candidate for ovarian cancer, built on NEUVOGEN's proprietary activation technology platform.

10NGEN-123
CategoryTherapeutic Cancer Vaccine
Description

NGEN-123 is a therapeutic cancer vaccine product candidate for pancreatic cancer, built on NEUVOGEN's proprietary activation technology platform.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-28
Description

NEUVOGEN and ImaginAb signed a multi-year non-exclusive licensing agreement for ImaginAb's 89Zr CD8 Immuno-PET imaging technology. Under the agreement, ImaginAb provides clinical doses of CD8 Immuno-PET imaging agents for integration into NEUVOGEN's therapeutic vaccine clinical trials, along with technical and clinical support. ImaginAb's PET imaging technology enables tracking and quantitative imaging of CD8 T cells in cancer patients, allowing NEUVOGEN to visualize tumor infiltrating lymphocytes and monitor CD8 T cell dynamics in response to their cancer vaccine therapies without requiring multiple tumor biopsies. ImaginAb receives license fees and contingent payments.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Moderna is developing mRNA-based personalized neoantigen cancer vaccines (mRNA-4157/V940) in partnership with Merck, targeting solid tumors including NSCLC. It competes with NEUVOGEN for the same therapeutic cancer vaccine opportunity but uses a personalized, patient-specific mRNA approach rather than an off-the-shelf whole-cell platform.

TypeDirect peer
Description

BioNTech is developing mRNA-based cancer vaccines including BNT122 (autogene cevumeran) with Genentech/Roche, FixVac, and individualized neoantigen programs targeting solid tumors. It is the most advanced personalized cancer vaccine competitor to NEUVOGEN's whole-cell approach.

TypeDirect peer
Description

Gritstone bio develops neoantigen-based immunotherapies (GRANITE and SLATE programs) targeting solid tumors using viral vectors and self-amplifying mRNA. It is a direct competitor in the personalized/neoantigen cancer vaccine space serving similar oncology indications as NEUVOGEN.

TypeDirect peer
Description

CureVac is developing mRNA-based cancer vaccines (CV8102 and others) for solid tumors and is partnering with major pharma. It competes with NEUVOGEN for the therapeutic cancer vaccine opportunity using an off-the-shelf mRNA technology approach.

TypeEmerging player
Description

Nouscom is a clinical-stage biotech developing off-the-shelf and personalized neoantigen cancer vaccines using viral vectors. It is an emerging European player with overlapping therapeutic vaccine technology and solid tumor focus, comparable to NEUVOGEN's earlier-stage position.

TypeBroad incumbent
Description

Merck is the leader in immuno-oncology with Keytruda (pembrolizumab), which is the most likely combination backbone for any therapeutic cancer vaccine including NEUVOGEN's NGEN-143. Merck's partnership with Moderna for mRNA-4157 sets a template for how it could engage with NEUVOGEN through licensing or co-development.

7Bristol Myers Squibb
TypeBroad incumbent
Description

BMS markets Opdivo (nivolumab) and Yervoy (ipilimumab) and acquired Juno Therapeutics, giving it leadership in both checkpoint inhibitors and cellular immunotherapies. As a checkpoint inhibitor leader and acquirer of cell therapy companies, BMS is a logical large-pharma counterpart or acquirer for NEUVOGEN.

TypeBroad incumbent
Description

Dendreon developed and commercialized Provenge (sipuleucel-T), the first FDA-approved cellular immunotherapy for cancer (prostate cancer). Mark Frohlich, NEUVOGEN board member, was formerly CMO of Dendreon. Dendreon provides commercial precedent and reference points for the whole-cell cancer vaccine category NEUVOGEN operates in.

TypeEmerging player
Description

OSE Immunotherapeutics is developing Tedopi, a neoepitope-based therapeutic cancer vaccine in non-small cell lung cancer and other solid tumors. It is a direct emerging competitor in the off-the-shelf therapeutic cancer vaccine category where NEUVOGEN's NGEN-143 operates.

TypeEmerging player
Description

Nykode Therapeutics develops DNA-based vaccines using its modular Vaccibody technology, including therapeutic cancer vaccine programs partnered with Regeneron and others. It is an emerging player in the off-the-shelf therapeutic vaccine space targeting solid tumors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NEUVOGEN

Therapeutic Cancer Vaccinesneuvogen.com

NEUVOGEN is a San Diego-based, pre-revenue clinical-stage biotechnology company developing off-the-shelf, whole-cell therapeutic cancer vaccines built on a proprietary activation technology, with a pipeline of 10 candidates led by NGEN-143 for non-small cell lung cancer.

What NEUVOGEN does

NEUVOGEN is a San Diego-based, privately held, clinical-stage biotechnology company developing off-the-shelf, whole-cell therapeutic cancer vaccines for solid tumors. The company applies a systems biology and data-driven engineering approach to build each vaccine from six genetically modified allogeneic tumor cell lines, enhanced with a proprietary activation technology designed to overcome peripheral tolerance and broaden tumor antigen presentation. Its lead candidate, NGEN-143, targets non-small cell lung cancer (NSCLC) and is supported by preclinical in vitro and in vivo data, including AACR 2025 data showing polyfunctional CD8+ T cell activation and improved survival when combined with anti-PD1 in mouse tumor models. The company has expanded a pipeline of 10 candidates (NGEN-143, -241, -121, -221, -181, -281, -261, -122, -242, -123) spanning NSCLC, prostate, colorectal, breast, head & neck, glioblastoma, bladder, gastric, ovarian, and pancreatic cancers.

The company is pre-revenue and not yet in clinical trials. Its business model contemplates future revenue from product sales following regulatory approval, supplemented by potential licensing, co-development, or acquisition transactions with larger pharmaceutical partners. Commercial distribution is expected to flow through hospital and specialty pharmacies and oncology centers, with the company signaling openness to partnership-based global commercialization. Scientific credibility has been reinforced by SAB additions including 2018 Nobel laureate James P. Allison and Padmanee Sharma of MD Anderson, and board leadership by former Amgen CEO Gordon Binder. A 2022 licensing agreement with ImaginAb provides CD8 Immuno-PET imaging for clinical trial pharmacodynamic readouts. No commercial customers, funding rounds, or revenue figures are disclosed in the available source data.

NEUVOGEN firmographics

Firmographics
Name
NEUVOGEN
Legal name
NEUVOGEN, Inc.
Website
https://neuvogen.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
NEUVOGEN is a San Diego-based, pre-revenue clinical-stage biotechnology company developing off-the-shelf, whole-cell therapeutic cancer vaccines built on a proprietary activation technology, with a pipeline of 10 candidates led by NGEN-143 for non-small cell lung cancer.
Ownership category
akta.pro rank

NEUVOGEN industry classification

Industry
Product category
Therapeutic Cancer Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Cancer vaccines
  • Whole cell immunotherapy
  • Solid tumor therapeutics
  • Immunoncology vaccines
  • Allogeneic cell therapy

Where NEUVOGEN is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NEUVOGEN business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Therapeutic Cancer Vaccines: NEUVOGEN is a pre-revenue clinical-stage biotechnology company developing therapeutic whole cell cancer vaccines. The company has not yet commercialized any products. Revenue generation is expected through product sales following regulatory approval, with potential for licensing agreements, co-development partnerships, or outright acquisition by larger pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

NEUVOGEN product offering

Product offering

Core offering

NEUVOGEN develops therapeutic whole cell cancer vaccines for solid tumor indications using a proprietary platform that combines six genetically modified allogeneic tumor cell lines per vaccine product. Each cell line is enhanced with proprietary activation technology to broaden tumor antigen presentation and drive broad T cell responses. Vaccines are manufactured as off-the-shelf, intradermally administered products, with the lead candidate NGEN-143 targeting non-small cell lung cancer and nine additional candidates covering prostate, colorectal, breast, head and neck, glioblastoma, bladder, gastric, ovarian, and pancreatic cancers.

Product overview

NEUVOGEN is a biotechnology company developing a platform of therapeutic whole cell cancer vaccines for solid tumors. The company's portfolio consists of ten product candidates (NGEN-143, NGEN-241, NGEN-121, NGEN-221, NGEN-181, NGEN-281, NGEN-261, NGEN-122, NGEN-242, and NGEN-123) targeting non-small cell lung cancer, prostate cancer, colorectal cancer, breast cancer, head and neck cancer, glioblastoma, bladder cancer, gastric cancer, ovarian cancer, and pancreatic cancer respectively. NGEN-143 for NSCLC is the lead program. Each vaccine is built on NEUVOGEN's proprietary whole tumor cell vaccine platform, which combines advanced bioinformatics for cell line selection, proprietary genetic engineering for enhanced tumor antigen expression, and a scalable manufacturing process. All products are designed as off-the-shelf, intradermally administered vaccines.

Differentiator

Problem solved

Functional benefit

Brands

  • NGEN-143: Lead product candidate - off-the-shelf therapeutic vaccine for non-small cell lung cancer (NSCLC), comprising six genetically modified allogeneic tumor cell lines enhanced with proprietary activation technology
  • NGEN-241
  • NGEN-121
  • NGEN-221
  • NGEN-181
  • NGEN-281
  • NGEN-261
  • NGEN-122
  • NGEN-242
  • NGEN-123

Products and services

  • NGEN-143 NGEN-143 is NEUVOGEN's lead product candidate: an off-the-shelf therapeutic vaccine for non-small cell lung cancer (NSCLC) comprising six genetically modified allogeneic tumor cell lines, each enhanced with proprietary activation technology to broaden tumor antigen presentation and improve immune engagement. It is intended for oncology use and is administered intradermally in any clinical setting without patient-specific customization.
  • NGEN-241 NGEN-241 is a therapeutic cancer vaccine product candidate for prostate cancer, built on NEUVOGEN's proprietary activation technology platform.
  • NGEN-121 NGEN-121 is a therapeutic cancer vaccine product candidate for colorectal cancer, built on NEUVOGEN's proprietary activation technology platform.
  • NGEN-221 NGEN-221 is a therapeutic cancer vaccine product candidate for breast cancer, built on NEUVOGEN's proprietary activation technology platform.
  • NGEN-181 NGEN-181 is a therapeutic cancer vaccine product candidate for head and neck cancer, built on NEUVOGEN's proprietary activation technology platform.
  • NGEN-281 NGEN-281 is a therapeutic cancer vaccine product candidate for glioblastoma (GBM), built on NEUVOGEN's proprietary activation technology platform.
  • NGEN-261 NGEN-261 is a therapeutic cancer vaccine product candidate for bladder cancer, built on NEUVOGEN's proprietary activation technology platform.
  • NGEN-122 NGEN-122 is a therapeutic cancer vaccine product candidate for gastric cancer, built on NEUVOGEN's proprietary activation technology platform.
  • NGEN-242 NGEN-242 is a therapeutic cancer vaccine product candidate for ovarian cancer, built on NEUVOGEN's proprietary activation technology platform.
  • NGEN-123 NGEN-123 is a therapeutic cancer vaccine product candidate for pancreatic cancer, built on NEUVOGEN's proprietary activation technology platform.

Quantifiable outcome

  • NGEN-143 activates polyfunctional, cytotoxic T cells that efficiently kill human tumor cells in a caspase-3 dependent manner
  • +2 more outcomes

Companies that use NEUVOGEN

Customer profile

Segments2 records

Ideal customer profiles2 records

NEUVOGEN technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

NEUVOGEN partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ImaginAbcoreTechnology or Integration · 28 January 2021NEUVOGEN and ImaginAb signed a multi-year non-exclusive licensing agreement for ImaginAb's 89Zr CD8 Immuno-PET imaging technology. Under the agreement, ImaginAb provides clinical doses of CD8 Immuno-PET imaging agents for integration into NEUVOGEN's therapeutic vaccine clinical trials, along with technical and clinical support. ImaginAb's PET imaging technology enables tracking and quantitative imaging of CD8 T cells in cancer patients, allowing NEUVOGEN to visualize tumor infiltrating lymphocytes and monitor CD8 T cell dynamics in response to their cancer vaccine therapies without requiring multiple tumor biopsies. ImaginAb receives license fees and contingent payments.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

NEUVOGEN competitors and assessment

Company assessment

Direct peers

  • Moderna: Moderna is developing mRNA-based personalized neoantigen cancer vaccines (mRNA-4157/V940) in partnership with Merck, targeting solid tumors including NSCLC. It competes with NEUVOGEN for the same therapeutic cancer vaccine opportunity but uses a personalized, patient-specific mRNA approach rather than an off-the-shelf whole-cell platform.
  • BioNTech: BioNTech is developing mRNA-based cancer vaccines including BNT122 (autogene cevumeran) with Genentech/Roche, FixVac, and individualized neoantigen programs targeting solid tumors. It is the most advanced personalized cancer vaccine competitor to NEUVOGEN's whole-cell approach.
  • Gritstone bio: Gritstone bio develops neoantigen-based immunotherapies (GRANITE and SLATE programs) targeting solid tumors using viral vectors and self-amplifying mRNA. It is a direct competitor in the personalized/neoantigen cancer vaccine space serving similar oncology indications as NEUVOGEN.
  • CureVac: CureVac is developing mRNA-based cancer vaccines (CV8102 and others) for solid tumors and is partnering with major pharma. It competes with NEUVOGEN for the therapeutic cancer vaccine opportunity using an off-the-shelf mRNA technology approach.

Emerging players

  • Nouscom: Nouscom is a clinical-stage biotech developing off-the-shelf and personalized neoantigen cancer vaccines using viral vectors. It is an emerging European player with overlapping therapeutic vaccine technology and solid tumor focus, comparable to NEUVOGEN's earlier-stage position.
  • OSE Immunotherapeutics: OSE Immunotherapeutics is developing Tedopi, a neoepitope-based therapeutic cancer vaccine in non-small cell lung cancer and other solid tumors. It is a direct emerging competitor in the off-the-shelf therapeutic cancer vaccine category where NEUVOGEN's NGEN-143 operates.
  • Nykode Therapeutics (formerly Vaccibody): Nykode Therapeutics develops DNA-based vaccines using its modular Vaccibody technology, including therapeutic cancer vaccine programs partnered with Regeneron and others. It is an emerging player in the off-the-shelf therapeutic vaccine space targeting solid tumors.

Broad incumbents

  • Merck & Co. Merck is the leader in immuno-oncology with Keytruda (pembrolizumab), which is the most likely combination backbone for any therapeutic cancer vaccine including NEUVOGEN's NGEN-143. Merck's partnership with Moderna for mRNA-4157 sets a template for how it could engage with NEUVOGEN through licensing or co-development.
  • Bristol Myers Squibb: BMS markets Opdivo (nivolumab) and Yervoy (ipilimumab) and acquired Juno Therapeutics, giving it leadership in both checkpoint inhibitors and cellular immunotherapies. As a checkpoint inhibitor leader and acquirer of cell therapy companies, BMS is a logical large-pharma counterpart or acquirer for NEUVOGEN.
  • Dendreon (Sanpower Group): Dendreon developed and commercialized Provenge (sipuleucel-T), the first FDA-approved cellular immunotherapy for cancer (prostate cancer). Mark Frohlich, NEUVOGEN board member, was formerly CMO of Dendreon. Dendreon provides commercial precedent and reference points for the whole-cell cancer vaccine category NEUVOGEN operates in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

NEUVOGEN social profiles

Digital presence

NEUVOGEN financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NEUVOGEN leadership team

Management profile

Number of profiles

Profiles20 records

NEUVOGEN funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NEUVOGEN M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NEUVOGEN

What does NEUVOGEN do?

NEUVOGEN develops therapeutic whole cell cancer vaccines for solid tumor indications using a proprietary platform that combines six genetically modified allogeneic tumor cell lines per vaccine product. Each cell line is enhanced with proprietary activation technology to broaden tumor antigen presentation and drive broad T cell responses. Vaccines are manufactured as off-the-shelf, intradermally administered products, with the lead candidate NGEN-143 targeting non-small cell lung cancer and nine additional candidates covering prostate, colorectal, breast, head and neck, glioblastoma, bladder, gastric, ovarian, and pancreatic cancers.

Is NEUVOGEN a public or private company?

NEUVOGEN is a private company. It is classified as venture growth investor backed and is currently operating.

When was NEUVOGEN founded?

NEUVOGEN was founded in -1. It employs 11 to 50 people.

Where is NEUVOGEN based?

NEUVOGEN is headquartered in San Diego, United States, in the North America region.

How does NEUVOGEN make money?

One revenue line is on record: therapeutic Cancer Vaccines.

Who are NEUVOGEN's main competitors?

Direct peers on record are Moderna, BioNTech, Gritstone bio and CureVac. Emerging players are Nouscom, OSE Immunotherapeutics and Nykode Therapeutics (formerly Vaccibody). Broad incumbents are Merck & Co., Bristol Myers Squibb and Dendreon (Sanpower Group).

Does NEUVOGEN have an API?

No public API is recorded for NEUVOGEN.

What industry is NEUVOGEN in?

NEUVOGEN's product category is Therapeutic Cancer Vaccines. Its primary akta.pro industry code is HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection), with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNEUVOGEN Announces Poster Presentation at the American Association of Cancer Research Annual MeetingNEUVOGEN, Inc., a San Diego-based biotechnology company, announced it will present preclinical data at the AACR Annual Meeting on April 29, 2025, showing that its next-generation whole tumor cell vaccine NGEN-143 activates T cells recognizing a diverse antigen repertoire. The vaccine demonstrated efficacy in both immune warm and immune cold mouse tumor models, and improved survival when combined with anti-PD1 therapy. NEUVOGEN's lead product candidate is being developed as an off-the-shelf treatment for non-small cell lung cancer.PR NewswireNEUVOGEN Appoints Biotechnology Veteran, Mark Backer, PhD as Head of Technical OperationsNEUVOGEN appointed Mark Backer, PhD as Head of Technical Operations to lead technical operations and chemistry, manufacturing, and controls (CMC) technical development for the company's cancer vaccine pipeline. Dr. Backer brings over 35 years of biopharmaceutical industry experience, including founding Molecular Medicine BioServices and serving in executive roles at companies including Genentech, Vaxart, and Jennerex. The appointment is intended to support NEUVOGEN's transition into clinical testing as the company advances its whole cell cancer vaccine therapies.PR NewswireNEUVOGEN Announces Appointment of Chief Financial OfficerNEUVOGEN, an immunoncology company based in San Diego, has appointed George Montgomery as Chief Financial Officer. Montgomery brings over three decades of experience in capital raising and healthcare banking, having previously served as CFO at Coherus BioSciences and held senior roles at JPMorgan H&Q and Cowen & Company. The company states it is at an inflection point as it advances its cancer vaccine programs into clinical development.PR NewswireNEUVOGEN Appoints Cellular Immune Therapy Expert, Dr. Jack Bui to its Scientific Advisory BoardNEUVOGEN, an immunoncology company, has appointed Dr. Jack Bui to its Scientific Advisory Board effective August 30, 2021. Dr. Bui, Director of UC San Diego's Stem Cell Processing Laboratory and Flow Cytometry and Immunology Laboratory, brings expertise in tumor immunology and immune monitoring that will guide the design and execution of NEUVOGEN's clinical studies for cancer vaccines targeting solid tumors. The appointment is intended to advance NEUVOGEN's pipeline of whole cell cancer vaccine therapies.PR NewswireNEUVOGEN Appoints Dr. Mark W. Frohlich, a World-Renowned Immunotherapy Expert to its Board of Directors and Scientific Advisory BoardNEUVOGEN announced the appointment of Dr. Mark W. Frohlich to its Board of Directors and Scientific Advisory Board, effective August 23, 2021. Dr. Frohlich brings over two decades of experience in cellular immunotherapy development for cancer, having led the U.S. and European approval of Provenge at Dendreon and served as Executive Vice President at Juno Therapeutics. The company stated his expertise will help advance its off-the-shelf cancer vaccine platform into clinical development for solid tumors.PR NewswireNEUVOGEN Appoints Life Sciences Legal Advisor, Alan C. Mendelson to Board of DirectorsNEUVOGEN announced the appointment of Alan C. Mendelson to its Board of Directors effective February 23, 2021. Mendelson is a veteran life sciences legal advisor who spent 20 years as a partner at Latham & Watkins LLP before retiring in December 2020, and previously held roles at Cooley LLP and served as acting General Counsel at Amgen Inc. and Cadence Design Systems. He will provide guidance on business and legal matters as NEUVOGEN advances its cancer vaccine candidates for solid tumors.PR NewswireImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET TechnologyImaginAb Inc and NEUVOGEN signed a multi-year non-exclusive licensing agreement in January 2021, under which ImaginAb will provide its 89Zr CD8 Immuno-PET imaging technology for use in NEUVOGEN's therapeutic cancer vaccine clinical trials. ImaginAb will receive license fees and contingent payments in exchange for supplying clinical doses, technical support, and clinical support services. The imaging technology enables non-invasive tracking and quantification of CD8 T cells in solid tumors, allowing NEUVOGEN to monitor immune responses to its cancer vaccines without requiring multiple tumor biopsies.PR NewswireNEUVOGEN Appoints Dr. Christian Ottensmeier Head of Scientific Advisory BoardNEUVOGEN, an immuno-oncology company based in San Diego, announced the appointment of Dr. Christian Ottensmeier as Head of its Scientific Advisory Board. Dr. Ottensmeier, a Professor of Immuno-Oncology at the University of Liverpool and Adjunct Professor at the La Jolla Institute for Immunology, brings expertise in tumor-antigen specific immunity and cancer vaccine research. The company highlighted its preclinical data demonstrating the ability of its proprietary adjuvant strategy to prime immune responses against tumor-associated self-proteins.PR NewswireNEUVOGEN Announces Participation at B. Riley Virtual Oncology Investor ConferenceNEUVOGEN Inc. announced that its CEO Todd Binder will participate in the B. Riley Virtual Oncology Investor Conference on January 21, 2021, at 3:00 PM Eastern Time. The company stated that investors can access the webcast through a provided link. NEUVOGEN is an immunotherapy company based in San Diego, California focused on developing therapeutic cancer vaccines.PR NewswireNEUVOGEN Announces Next Generation Cancer Vaccine Strategy to Transform how Solid Tumors are TreatedNEUVOGEN announced its next-generation whole cell cancer vaccine strategy for treating solid tumors, stating it has completed pre-clinical validation of its technology platform with early data showing potential to improve patient outcomes. The company claims its approach addresses three key limitations of past cancer vaccine efforts: inadequate tumor target breadth, inadequate immune priming, and lack of a systematic approach to overcome immune suppressive mechanisms. NEUVOGEN, led by a team with experience at Amgen, Juno Therapeutics, and other biotech firms, plans to advance its pipeline candidates into clinical development.